抗凝固薬中和薬の世界市場レポート 2025年

抗凝固薬中和薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR10.2％で24億8,000万米ドルに成長します。予測期間中の成長は、解毒剤に対する需要の高まり、ヘルスケアインフラの改善、血栓塞栓性疾患の罹患率の増加、心血管疾患の有病率の増加、啓発キャンペーンの拡大などに起因すると考えられます。予測期間に予想される主な動向には、技術の進歩、AI主導の創薬、ナノ医療の進展、デジタルヘルスソリューションの統合、医薬品供給管理におけるブロックチェーンの利用などが含まれます。

心血管疾患（CVDs）の有病率の増加は、抗凝固薬中和薬市場の拡大を促進すると予想されます。冠動脈疾患、脳卒中、心不全などの心臓や血管の障害を包括するCVDは、主に生活習慣の乱れが原因で増加傾向にあります。加工食品の消費量の増加、運動不足、高いストレスレベルなどの要因が、肥満、高血圧、糖尿病の原因となっています。心房細動や深部静脈血栓症などで血液希釈剤を服用している患者は、正常な血液凝固を回復させるために迅速な介入を必要とする生命を脅かす出血に直面する可能性があるため、CVD患者はしばしば過剰な出血リスクを軽減するために抗凝固薬中和薬を必要とします。例えば、2024年12月、Office for Health Improvement and Disparitiesは、2023年3月までの会計年度において、イングランドの187万9,000人（3％）が冠動脈性心疾患（CHD）のGP診断を受けたと報告しました。心不全入院率の地域差はCHDよりも顕著で、4倍の差が認められ、ハウンズローでは人口10万人当たり396.5人の入院でピークに達しました。このような心血管疾患の急増が、抗凝固薬中和薬市場の成長を後押ししています。

抗凝固薬中和薬市場の主なプレーヤーは、治療効果を高め、患者の安全性を確保するため、技術革新、特に新しい逆転剤の開発に注力しています。これらの逆転薬は、抗凝固薬中和薬の作用を迅速かつ選択的に打ち消すように設計された特殊な治療薬であり、血液をサラサラにする薬剤を迅速かつ効率的に逆転させる。例えば、2022年3月、英国の製薬・バイオテクノロジー企業であるアストラゼネカは、生命を脅かす出血時に第Xa因子阻害剤（アピキサバン、リバーロキサバン、エドキサバンなど）の作用を逆転させるオンデキサ（アンデキサネットアルファ）の承認を日本で取得しました。本剤は、抗Xa活性を迅速かつ効果的に逆転させる能力を実証したANNEXA-4試験に基づいて、この目的で日本で初めて承認された薬剤です。この承認は、一般的に処方されるこれらの抗凝固薬中和薬に伴う主要な出血リスクに対処するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の抗凝固薬中和薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗凝固薬中和薬市場：成長率分析
• 世界の抗凝固薬中和薬市場の実績：規模と成長, 2019-2024
• 世界の抗凝固薬中和薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の抗凝固薬中和薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗凝固薬中和薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロトロンビン複合体濃縮物
• フィトナジオン（ビタミンK）
• アンデキサネットアルファ
• イダルシズマブ
• プロタミン
• その他の製品タイプ
• 世界の抗凝固薬中和薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射
• 経口
• 世界の抗凝固薬中和薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の抗凝固薬中和薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接経口抗凝固薬中和薬（DOAC）の拮抗作用
• ワルファリンの逆転
• ヘパリンと低分子量ヘパリン（LMWH）の逆転
• その他の用途
• 世界の抗凝固薬中和薬市場、プロトロンビン複合体濃縮物（PCC）、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 3要素PCC
• 4要素PCC
• 活性化PCC（aPCC）
• 世界の抗凝固薬中和薬市場、フィトナジオン（ビタミンK）、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ビタミンK
• 静脈内（IV）ビタミンK
• 皮下（SC）ビタミンK
• 世界の抗凝固薬中和薬市場、アンデキサネットアルファ、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• FXa阻害薬（アピキサバン、リバーロキサバン）の拮抗作用
• 他の抗凝固薬中和薬の適応外使用
• 世界の抗凝固薬中和薬市場、イダルシズマブ、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• ダビガトラン誘発性抗凝固の中和
• 緊急手術での中和薬
• 世界の抗凝固薬中和薬市場、プロタミン、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘパリン拮中和の硫酸プロタミン
• 低分子量ヘパリン（LMWH）中和を有するプロタミン変異体
• 世界の抗凝固薬中和薬市場、その他の製品タイプ、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 組換え因子VIIa（rFVIIa）
• 新鮮凍結血漿（FFP）
• デスモプレシン（DDAVP）
• 活性炭（DOAC中和）

第7章 地域別・国別分析

• 世界の抗凝固薬中和薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗凝固薬中和薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗凝固薬中和薬市場：競合情勢
• 抗凝固薬中和薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• CSL Behring LLC
• Daiichi Sankyo Company Limited
• Avantor Inc.
• Daicel Pharma Services GmbH
• Octapharma AG
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• AMAG Pharmaceuticals Inc
• Glenmark Pharmaceuticals Inc USA
• Alexion Pharmaceuticals Inc
• Amphastar Pharmaceuticals Inc
• Portola Pharmaceuticals Inc
• Transo-Pharm USA LLC
• Join Hub Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗凝固薬中和薬市場2029：新たな機会を提供する国
• 抗凝固薬中和薬市場2029：新たな機会を提供するセグメント
• 抗凝固薬中和薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anticoagulant reversal drugs are medications used to counteract the effects of anticoagulants, helping restore normal blood clotting in patients experiencing excessive bleeding. These drugs are typically administered in emergency situations, such as life-threatening hemorrhages or urgent surgeries, to quickly reverse anticoagulation and prevent severe complications.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary anticoagulant reversal drugs include prothrombin complex concentrates, phytonadione (vitamin K), andexanet alfa, idarucizumab, protamine, and others. Prothrombin complex concentrates (PCCs) are blood-derived products containing clotting factors that help manage excessive bleeding. They can be administered via both injectable and oral routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. PCCs are used for reversing direct oral anticoagulants (DOACs), warfarin, heparin, low-molecular-weight heparin (LMWH), and other anticoagulant treatments.

The anticoagulant reversal drugs market research report is one of a series of new reports from The Business Research Company that provides anticoagulant reversal drugs market statistics, including anticoagulant reversal drugs industry global market size, regional shares, competitors with a anticoagulant reversal drugs market share, detailed anticoagulant reversal drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulant reversal drugs industry. This anticoagulant reversal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticoagulant reversal drugs market size has grown strongly in recent years. It will grow from$1.52 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the increase in bleeding disorders, the growing elderly population, expanded healthcare spending, a rise in the prevalence of strokes, and increased investments in the pharmaceutical sector.

The anticoagulant reversal drugs market size is expected to see strong growth in the next few years. It will grow to$2.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth during the forecast period can be attributed to the rising demand for antidotes, improvements in healthcare infrastructure, an increasing incidence of thromboembolic disorders, a growing prevalence of cardiovascular diseases, and expanded awareness campaigns. Key trends expected in the forecast period include technological advancements, AI-driven drug discovery, progress in nanomedicine, the integration of digital health solutions, and the use of blockchain in drug supply management.

The growing prevalence of cardiovascular diseases (CVDs) is expected to drive the expansion of the anticoagulant reversal drugs market. CVDs, which encompass heart and blood vessel disorders such as coronary artery disease, stroke, and heart failure, are on the rise, largely due to poor lifestyle choices. Factors such as increased consumption of processed foods, lack of physical activity, and high stress levels contribute to obesity, hypertension, and diabetes. Patients with CVDs often require anticoagulant reversal drugs to mitigate excessive bleeding risks, as individuals on blood thinners for conditions such as atrial fibrillation or deep vein thrombosis may face life-threatening hemorrhages that demand quick intervention to restore normal blood clotting. For example, in December 2024, the Office for Health Improvement and Disparities reported that, in the financial year ending March 2023, 1,879,000 people (3%) in England had a GP diagnosis of coronary heart disease (CHD). Regional variations in heart failure admission rates were more pronounced than for CHD, with a fourfold difference observed, peaking at 396.5 admissions per 100,000 people in Hounslow. This surge in cardiovascular diseases is, therefore, fueling the growth of the anticoagulant reversal drugs market.

Key players in the anticoagulant reversal drugs market are focusing on innovation, particularly the development of new reversal agents, to enhance treatment effectiveness and ensure patient safety. These reversal agents are specialized therapeutics designed to rapidly and selectively counteract the effects of anticoagulants, providing swift and efficient reversal of blood-thinning medications. For example, in March 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, received approval for Ondexxya (andexanet alfa) in Japan to reverse the effects of Factor Xa inhibitors (such as apixaban, rivaroxaban, and edoxaban) during life-threatening bleeds. This was the first approved drug in Japan for this purpose, based on the ANNEXA-4 trial, which demonstrated its ability to rapidly and effectively reverse anti-FXa activity. This approval addresses the major bleeding risks associated with these commonly prescribed anticoagulant drugs.

In February 2025, Novartis AG, a pharmaceutical giant based in Switzerland, acquired Anthos Therapeutics Inc. for $3.1 billion. This acquisition aims to bolster Novartis's cardiovascular portfolio with abelacimab, a next-generation anticoagulant designed to reduce blood clot risks while minimizing bleeding complications. Anthos Therapeutics Inc., a US-based biopharmaceutical company, specializes in developing innovative anticoagulant therapies to address thrombosis-related disorders.

Major players in the anticoagulant reversal drugs market are Pfizer Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, CSL Behring LLC, Daiichi Sankyo Company Limited, Avantor Inc., Daicel Pharma Services GmbH, Octapharma AG, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, AMAG Pharmaceuticals Inc, Glenmark Pharmaceuticals Inc USA, Alexion Pharmaceuticals Inc, Amphastar Pharmaceuticals Inc, Portola Pharmaceuticals Inc, Transo-Pharm USA LLC, and Join Hub Pharma.

North America was the largest region in the anticoagulant reversal drugs market in 2024. The regions covered in anticoagulant reversal drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anticoagulant reversal drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticoagulant reversal drugs market consists of sales of fresh frozen plasma, tranexamic acid, desmopressin, activated charcoal, and recombinant factor vIIa. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anticoagulant Reversal Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anticoagulant reversal drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anticoagulant reversal drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anticoagulant reversal drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Prothrombin Complex Concentrates; Phytonadione (Vitamin K); Andexanet Alfa; Idarucizumab; Protamine; Other Product Types
• 2) By Route of Administration: Injectable; Oral
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By Application: Direct Oral Anticoagulant (DOAC) Reversal; Warfarin Reversal; Heparin And Low-Molecular-Weight Heparin (LMWH) Reversal; Other Applications
• Subsegments:
• 1) By Prothrombin Complex Concentrates (PCCs): 3-Factor PCC; 4-Factor PCC; Activated PCC (aPCC)
• 2) By Phytonadione (Vitamin K): Oral Vitamin K; Intravenous (IV) Vitamin K; Subcutaneous (SC) Vitamin K
• 3) By Andexanet Alfa: Reversal of Factor Xa Inhibitors (Apixaban, Rivaroxaban); Off-label Usage In Other Anticoagulants
• 4) By Idarucizumab: Reversal of Dabigatran-induced Anticoagulation; Emergency Surgical Reversal
• 5) By Protamine: Protamine Sulfate For Heparin Reversal; Protamine Variants For Low Molecular Weight Heparin (LMWH) Reversal
• 6) By Other Product Types: Recombinant Factor VIIa (rFVIIa); Fresh Frozen Plasma (FFP); Desmopressin (DDAVP); Activated Charcoal (For DOAC Reversal)
• Companies Mentioned: Pfizer Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anticoagulant Reversal Drugs Market Characteristics

3. Anticoagulant Reversal Drugs Market Trends And Strategies

4. Anticoagulant Reversal Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anticoagulant Reversal Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anticoagulant Reversal Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anticoagulant Reversal Drugs Market Growth Rate Analysis
• 5.4. Global Anticoagulant Reversal Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anticoagulant Reversal Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anticoagulant Reversal Drugs Total Addressable Market (TAM)

6. Anticoagulant Reversal Drugs Market Segmentation

• 6.1. Global Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prothrombin Complex Concentrates
• Phytonadione (Vitamin K)
• Andexanet Alfa
• Idarucizumab
• Protamine
• Other Product Types
• 6.2. Global Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• 6.3. Global Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Anticoagulant Reversal Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Oral Anticoagulant (DOAC) Reversal
• Warfarin Reversal
• Heparin And Low-Molecular-Weight Heparin (LMWH) Reversal
• Other Applications
• 6.5. Global Anticoagulant Reversal Drugs Market, Sub-Segmentation Of Prothrombin Complex Concentrates (PCCs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 3-Factor PCC
• 4-Factor PCC
• Activated PCC (aPCC)
• 6.6. Global Anticoagulant Reversal Drugs Market, Sub-Segmentation Of Phytonadione (Vitamin K), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Vitamin K
• Intravenous (IV) Vitamin K
• Subcutaneous (SC) Vitamin K
• 6.7. Global Anticoagulant Reversal Drugs Market, Sub-Segmentation Of Andexanet Alfa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reversal of Factor Xa Inhibitors (Apixaban, Rivaroxaban)
• Off-label Usage In Other Anticoagulants
• 6.8. Global Anticoagulant Reversal Drugs Market, Sub-Segmentation Of Idarucizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reversal of Dabigatran-induced Anticoagulation
• Emergency Surgical Reversal
• 6.9. Global Anticoagulant Reversal Drugs Market, Sub-Segmentation Of Protamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protamine Sulfate for Heparin Reversal
• Protamine Variants For Low Molecular Weight Heparin (LMWH) Reversal
• 6.10. Global Anticoagulant Reversal Drugs Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Factor VIIa (rFVIIa)
• Fresh Frozen Plasma (FFP)
• Desmopressin (DDAVP)
• Activated Charcoal (for DOAC Reversal)

7. Anticoagulant Reversal Drugs Market Regional And Country Analysis

• 7.1. Global Anticoagulant Reversal Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anticoagulant Reversal Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anticoagulant Reversal Drugs Market

• 8.1. Asia-Pacific Anticoagulant Reversal Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anticoagulant Reversal Drugs Market

• 9.1. China Anticoagulant Reversal Drugs Market Overview
• 9.2. China Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anticoagulant Reversal Drugs Market

• 10.1. India Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anticoagulant Reversal Drugs Market

• 11.1. Japan Anticoagulant Reversal Drugs Market Overview
• 11.2. Japan Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anticoagulant Reversal Drugs Market

• 12.1. Australia Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anticoagulant Reversal Drugs Market

• 13.1. Indonesia Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anticoagulant Reversal Drugs Market

• 14.1. South Korea Anticoagulant Reversal Drugs Market Overview
• 14.2. South Korea Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anticoagulant Reversal Drugs Market

• 15.1. Western Europe Anticoagulant Reversal Drugs Market Overview
• 15.2. Western Europe Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anticoagulant Reversal Drugs Market

• 16.1. UK Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anticoagulant Reversal Drugs Market

• 17.1. Germany Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anticoagulant Reversal Drugs Market

• 18.1. France Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anticoagulant Reversal Drugs Market

• 19.1. Italy Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anticoagulant Reversal Drugs Market

• 20.1. Spain Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anticoagulant Reversal Drugs Market

• 21.1. Eastern Europe Anticoagulant Reversal Drugs Market Overview
• 21.2. Eastern Europe Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anticoagulant Reversal Drugs Market

• 22.1. Russia Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anticoagulant Reversal Drugs Market

• 23.1. North America Anticoagulant Reversal Drugs Market Overview
• 23.2. North America Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anticoagulant Reversal Drugs Market

• 24.1. USA Anticoagulant Reversal Drugs Market Overview
• 24.2. USA Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anticoagulant Reversal Drugs Market

• 25.1. Canada Anticoagulant Reversal Drugs Market Overview
• 25.2. Canada Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anticoagulant Reversal Drugs Market

• 26.1. South America Anticoagulant Reversal Drugs Market Overview
• 26.2. South America Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anticoagulant Reversal Drugs Market

• 27.1. Brazil Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anticoagulant Reversal Drugs Market

• 28.1. Middle East Anticoagulant Reversal Drugs Market Overview
• 28.2. Middle East Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anticoagulant Reversal Drugs Market

• 29.1. Africa Anticoagulant Reversal Drugs Market Overview
• 29.2. Africa Anticoagulant Reversal Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anticoagulant Reversal Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anticoagulant Reversal Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anticoagulant Reversal Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anticoagulant Reversal Drugs Market Competitive Landscape
• 30.2. Anticoagulant Reversal Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Anticoagulant Reversal Drugs Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. CSL Behring LLC
• 31.3. Daiichi Sankyo Company Limited
• 31.4. Avantor Inc.
• 31.5. Daicel Pharma Services GmbH
• 31.6. Octapharma AG
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Amneal Pharmaceuticals LLC
• 31.9. AMAG Pharmaceuticals Inc
• 31.10. Glenmark Pharmaceuticals Inc USA
• 31.11. Alexion Pharmaceuticals Inc
• 31.12. Amphastar Pharmaceuticals Inc
• 31.13. Portola Pharmaceuticals Inc
• 31.14. Transo-Pharm USA LLC
• 31.15. Join Hub Pharma

32. Global Anticoagulant Reversal Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anticoagulant Reversal Drugs Market

34. Recent Developments In The Anticoagulant Reversal Drugs Market

35. Anticoagulant Reversal Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Anticoagulant Reversal Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anticoagulant Reversal Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anticoagulant Reversal Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34760_Anticoagulant_Reversal_Drugs_GMR_2025